Technology
Health
Pharmaceutical

Evoke Pharma

$0.61
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0103 (-1.70%) Today
+$0.0153 (2.57%) After Hours

Why Robinhood?

You can buy or sell Evoke Pharma and other stocks, options, ETFs, and crypto commission-free!

About

Evoke Pharma, Inc. Common Stock, also called Evoke Pharma, is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. Read More It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Employees
6
Headquarters
Solana Beach, California
Founded
2007
Market Cap
10.63M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
292.17K
High Today
$0.6171
Low Today
$0.56
Open Price
$0.581
Volume
72.56K
52 Week High
$3.40
52 Week Low
$0.56

Collections

Technology
Health
Pharmaceutical
2013 IPO
US
North America

News

NasdaqMay 8

Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?

Investor focus will remain on Evoke Pharma, Inc.'sEVOK progress and issues related to its new drug application (NDA) filling for Gimoti to treat diabetic gastroparesis when i t report s first-quarter 2019 earnings results. The company's performance over the trailing four quarters has been encouraging with its earnings having surpassed expectations twice while missing the same just once and delivering in-line results on another occasion. The average previous four-quarter negative surprise is 3.40%. In the l...

429
Yahoo FinanceApr 29

Investors Who Bought Evoke Pharma (NASDAQ:EVOK) Shares Five Years Ago Are Now Down 92%

1,127

Earnings

-$0.34
-$0.25
-$0.16
-$0.07
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.07 per share
Actual
-$0.11 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.